{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fraisinghealth.simplecast.com%2Fepisodes%2Fthe-consolidated-drug-channel-qtgWgYbZ","width":444,"version":"1.0","type":"rich","title":"The Consolidated Drug Channel and Cash-Pay Drugs","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/8bfdd457-9cd9-4577-bbed-a027587c6960/103ea12d-dd5b-4ef8-b398-ddf54dfbe24e/cover-art-3000x3000-no-grain-2.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/36d5e9aa-367f-4c73-b1c1-ab8ce6d0bb97\" height=\"200\" width=\"100%\" title=\"The Consolidated Drug Channel and Cash-Pay Drugs\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Bio+Health general partner Julie Yoo joins Adam Fein, the CEO of Drug Channels Institute, and Olivia Webb, the editorial lead for a16z Bio+Health, to discuss the consolidated pharmaceutical system."}